148 related articles for article (PubMed ID: 24753092)
1. Sclerostin deficiency is linked to altered bone composition.
Hassler N; Roschger A; Gamsjaeger S; Kramer I; Lueger S; van Lierop A; Roschger P; Klaushofer K; Paschalis EP; Kneissel M; Papapoulos S
J Bone Miner Res; 2014 Oct; 29(10):2144-51. PubMed ID: 24753092
[TBL] [Abstract][Full Text] [Related]
2. Patients with sclerosteosis and disease carriers: human models of the effect of sclerostin on bone turnover.
van Lierop AH; Hamdy NA; Hamersma H; van Bezooijen RL; Power J; Loveridge N; Papapoulos SE
J Bone Miner Res; 2011 Dec; 26(12):2804-11. PubMed ID: 21786318
[TBL] [Abstract][Full Text] [Related]
3. Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength.
Li X; Ominsky MS; Niu QT; Sun N; Daugherty B; D'Agostin D; Kurahara C; Gao Y; Cao J; Gong J; Asuncion F; Barrero M; Warmington K; Dwyer D; Stolina M; Morony S; Sarosi I; Kostenuik PJ; Lacey DL; Simonet WS; Ke HZ; Paszty C
J Bone Miner Res; 2008 Jun; 23(6):860-9. PubMed ID: 18269310
[TBL] [Abstract][Full Text] [Related]
4. Sclerostin deficiency in humans.
van Lierop AH; Appelman-Dijkstra NM; Papapoulos SE
Bone; 2017 Mar; 96():51-62. PubMed ID: 27742500
[TBL] [Abstract][Full Text] [Related]
5. Serum Dickkopf 1 levels in sclerostin deficiency.
van Lierop AH; Moester MJ; Hamdy NA; Papapoulos SE
J Clin Endocrinol Metab; 2014 Feb; 99(2):E252-6. PubMed ID: 24302746
[TBL] [Abstract][Full Text] [Related]
6. Novel SOST gene mutation in a sclerosteosis patient from Morocco: a case report.
Belkhribchia MR; Collet C; Laplanche JL; Hassani R
Eur J Med Genet; 2014 Mar; 57(4):133-7. PubMed ID: 24594238
[TBL] [Abstract][Full Text] [Related]
7. Bone matrix quality after sclerostin antibody treatment.
Ross RD; Edwards LH; Acerbo AS; Ominsky MS; Virdi AS; Sena K; Miller LM; Sumner DR
J Bone Miner Res; 2014 Jul; 29(7):1597-607. PubMed ID: 24470143
[TBL] [Abstract][Full Text] [Related]
8. The Lrp4R1170Q Homozygous Knock-In Mouse Recapitulates the Bone Phenotype of Sclerosteosis in Humans.
Boudin E; Yorgan T; Fijalkowski I; Sonntag S; Steenackers E; Hendrickx G; Peeters S; De Maré A; Vervaet B; Verhulst A; Mortier G; D'Haese P; Schinke T; Van Hul W
J Bone Miner Res; 2017 Aug; 32(8):1739-1749. PubMed ID: 28477420
[TBL] [Abstract][Full Text] [Related]
9. Genetics of Sost/SOST in sclerosteosis and van Buchem disease animal models.
Sebastian A; Loots GG
Metabolism; 2018 Mar; 80():38-47. PubMed ID: 29080811
[TBL] [Abstract][Full Text] [Related]
10. Pediatric reference Raman data for material characteristics of iliac trabecular bone.
Gamsjaeger S; Hofstetter B; Fratzl-Zelman N; Roschger P; Roschger A; Fratzl P; Brozek W; Masic A; Misof BM; Glorieux FH; Klaushofer K; Rauch F; Paschalis EP
Bone; 2014 Dec; 69():89-97. PubMed ID: 25245203
[TBL] [Abstract][Full Text] [Related]
11. Bone Matrix Composition Following PTH Treatment is Not Dependent on Sclerostin Status.
Ross RD; Mashiatulla M; Robling AG; Miller LM; Sumner DR
Calcif Tissue Int; 2016 Feb; 98(2):149-57. PubMed ID: 26514840
[TBL] [Abstract][Full Text] [Related]
12. Exendin-4 increases bone mineral density in type 2 diabetic OLETF rats potentially through the down-regulation of SOST/sclerostin in osteocytes.
Kim JY; Lee SK; Jo KJ; Song DY; Lim DM; Park KY; Bonewald LF; Kim BJ
Life Sci; 2013 Mar; 92(10):533-40. PubMed ID: 23357248
[TBL] [Abstract][Full Text] [Related]
13. Cortical bone adaptation to a moderate level of mechanical loading in male Sost deficient mice.
Yang H; Büttner A; Albiol L; Julien C; Thiele T; Figge C; Kramer I; Kneissel M; Duda GN; Checa S; Willie BM
Sci Rep; 2020 Dec; 10(1):22299. PubMed ID: 33339872
[TBL] [Abstract][Full Text] [Related]
14. Pigment epithelium derived factor suppresses expression of Sost/Sclerostin by osteocytes: implication for its role in bone matrix mineralization.
Li F; Song N; Tombran-Tink J; Niyibizi C
J Cell Physiol; 2015 Jun; 230(6):1243-9. PubMed ID: 25363869
[TBL] [Abstract][Full Text] [Related]
15. Sclerosteosis: Report of type 1 or 2 in three Indian Tamil families and literature review.
Whyte MP; Deepak Amalnath S; McAlister WH; Pedapati R; Muthupillai V; Duan S; Huskey M; Bijanki VN; Mumm S
Bone; 2018 Nov; 116():321-332. PubMed ID: 30077757
[TBL] [Abstract][Full Text] [Related]
16. Reversing LRP5-dependent osteoporosis and SOST deficiency-induced sclerosing bone disorders by altering WNT signaling activity.
Chang MK; Kramer I; Keller H; Gooi JH; Collett C; Jenkins D; Ettenberg SA; Cong F; Halleux C; Kneissel M
J Bone Miner Res; 2014 Jan; 29(1):29-42. PubMed ID: 23901037
[TBL] [Abstract][Full Text] [Related]
17. SOST/sclerostin, an osteocyte-derived negative regulator of bone formation.
van Bezooijen RL; ten Dijke P; Papapoulos SE; Löwik CW
Cytokine Growth Factor Rev; 2005 Jun; 16(3):319-27. PubMed ID: 15869900
[TBL] [Abstract][Full Text] [Related]
18. Osteocyte control of bone formation via sclerostin, a novel BMP antagonist.
Winkler DG; Sutherland MK; Geoghegan JC; Yu C; Hayes T; Skonier JE; Shpektor D; Jonas M; Kovacevich BR; Staehling-Hampton K; Appleby M; Brunkow ME; Latham JA
EMBO J; 2003 Dec; 22(23):6267-76. PubMed ID: 14633986
[TBL] [Abstract][Full Text] [Related]
19. First missense mutation in the SOST gene causing sclerosteosis by loss of sclerostin function.
Piters E; Culha C; Moester M; Van Bezooijen R; Adriaensen D; Mueller T; Weidauer S; Jennes K; de Freitas F; Löwik C; Timmermans JP; Van Hul W; Papapoulos S
Hum Mutat; 2010 Jul; 31(7):E1526-43. PubMed ID: 20583295
[TBL] [Abstract][Full Text] [Related]
20. Localization of SOST/sclerostin in cementocytes in vivo and in mineralizing periodontal ligament cells in vitro.
Jäger A; Götz W; Lossdörfer S; Rath-Deschner B
J Periodontal Res; 2010 Apr; 45(2):246-54. PubMed ID: 19778325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]